Emerging evidence has shown that
daphnoretin, one of the main active
ingredients of Daphne giraldii Nitsche, processes
antitumor activities in several tumor cells (e.g., colon cancer, lung
cancer, cervical cancer, and osteosarcoma). However, the antitumor
effect and its mechanism in breast cancer are unexplored. In this
study, our data indicated that daphnoretin obviously suppressed the
proliferation of breast cancer MCF-7 and MDA-MB-231 cells. Further
studies showed that daphnoretin remarkably increased the p21 level,
decreased cyclin E and CDK2 levels, and then arrested the cell cycle
at the S phase. Moreover, daphnoretin obviously lowered the BCL-2
level and raised the levels of BAX and cleaved caspase-9 and -3, leading
to cell apoptosis. Furthermore, daphnoretin remarkably decreased the
ratio of p-PI3K/PI3K and p-AKT/AKT in breast cancer cells. Collectively,
these findings demonstrated that daphnoretin could suppress breast
cancer cell proliferation through cell cycle arrest and inducing apoptosis,
which is related to the PI3K/AKT pathway.